PepGen Inc. - 8-K Filing

PepGen reports Q3 2026 results with $104.8M cash position and positive Phase 2 FREEDOM2-DM1 10 mg/kg topline data. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $PEPG

Read the full article at SEC EDGAR

Part of the story Veradermics, Inc - 8-K Filing (3 articles)

More Regulatory news